Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Genentech Announces FDA approval of Clinical Trial for Chugai's Actemra for COVID-19 Pneumonia

TOKYO, March 24, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on March 23 (local time) regarding the FDA approval of a clinical trial for Actemra®, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of hospitalized patients with severe COVID-19 pneumonia.

Please refer to the link below for details of the press release:

- Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia

https://www.gene.com/media/press-releases/14843/2020-03-23/genentech-announces-fda-approval-of-clin

[Note]

Roche Announces the Initiation of a Clinical Study of Chugai's Actemra for the Treatment of COVID-19 (A press release issued on March 19, 2020)

https://www.chugai-pharm.co.jp/english/news/detail/20200319154500_709.html

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp